Tongmai Jiangtang Capsule for Cardiovascular Clinical Outcomes in High-Risk Metabolic Syndrome Patients

NCT06908473 · tracked via the Priya Life Science China tracker

Sponsor

Guangdong Provincial Hospital of Traditional Chinese Medicine

Phase

Phase 3

Started

2025-04-24

Last updated

2025-06-13

Condition(s) studied

Metabolic SyndromeCardiovascular Disease (CKD)Cerebrovascular DiseaseQi Deficiency and Blood Stasis

Investigational drug(s) / intervention(s)

Participants will receive Tongmai Jiangtang Capsule (TJC) in addition to standard treatment.A placebo capsule that is identical in appearance, size, color, formulation, weight, taste, and smell to TJC

Participants will receive Tongmai Jiangtang Capsule (TJC) in addition to standard treatment.: Intervention Agent: The study employs Tongmai Jiangtang Capsule (TJC), a traditional Chinese medicine compound formulated based on TCM theory. It has the functions of Nourishing Yin, clearing heat and activating blood circulation, and can comprehensively regulate glucose and lipid metabolism as well as improve cardiovascular and cerebrovascular functions. Intervention Population: The study focuses on patients with metabolic syndrome at high cardiovascular and cerebrovascular risk (HCR-MS) who meet the TCM criteria for "Qi-deficiency and Blood Stasis syndrome," reflecting personalized and precision intervention. Intervention Design: A long-term study design with 26 weeks of intervention followed by 26 weeks of follow-up is adopted to comprehensively assess the short-term efficacy and long-term cardiovascular benefits of TJC. Control Design: The study employs a double-blind, randomized, placebo-controlled method.

A placebo capsule that is identical in appearance, size, color, formulation, weight, taste, and smell to TJC: Participants in this Arm will receive a placebo capsule that is identical in appearance, size, color, formulation, weight, taste, and smell to TJC, in addition to standard treatment.

Study summary

1. Conduct a large-sample, multicenter, superiority, double-blind, randomized controlled clinical trial to verify the efficacy of TJC in reducing the risk of cardiovascular and cerebrovascular events in patients with metabolic syndrome at high cardiovascular and cerebrovascular risk (HCR-MS).
2. Further construct an evaluation system for the long-term cardiovascular and cerebrovascular benefits of traditional Chinese medicine in regulating glucose and lipid metabolism through the evaluative study of the cardiovascular and cerebrovascular benefits of TJC.

Eligibility

Sex

ALL

Min age

65 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Age: Participants must be aged ≥65 years. * Participants must meet the diagnostic criteria for metabolic syndrome according to the 2020 Chinese Type 2 Diabetes Prevention Guidelines, which includes at least three of the following criteria:①Central obesity: Waist circumference ≥90 cm for men, ≥85 cm for women.②Hyperglycemia: Fasting blood glucose ≥6.1 mmol/L or 2-hour post-load glucose ≥7.8 mmol/L, or a confirmed diagnosis of diabetes with ongoing treatment.③Hypertension: Blood pressure ≥130/85 mmHg or a confirmed diagnosis of hypertension with ongoing treatment.④Elevated triglycerides (TG): ⑤Fasting TG ≥1.70 mmol/L. Low HDL cholesterol: Fasting HDL-C \<1.04 mmol/L. * Participants must meet the criteria for "Qi-deficiency and Blood Stasis" syndrome, which includes specific symptoms and signs such as fatigue, shortness of breath, stabbing pain, ecchymosis, and a tongue with purple discoloration or petechiae. * High Cardiovascular Risk: Participants must have at least one of the following: * History of myocardial infarction. * History of stroke or transient ischemic attack. ③History of coronary, carotid, or peripheral artery revascularization. * Coronary, carotid, or lower limb artery stenosis \>50%. ⑤Positive exercise stress test or documented symptomatic coronary heart disease, or unstable angina with ECG changes. * Chronic heart failure (NYHA Class II-III). ⑦Chronic kidney disease (eGFR \<60 ml/min/1.73m²). Exclusion Criteria: * Secondary Abnormalities: Secondary abnormalities in lipids, blood pressure, or blood glucose. * Type 1 Diabetes: Participants with Type 1 diabetes mellitus. * Special Populations: Pregnant or breastfeeding individuals, or those with a history of allergy to the study medication. * Recent Acute Events: Acute coronary or cerebrovascular events within the past 14 days. * Upcoming Revascularization: Planned coronary, carotid, or peripheral artery revascularization. * Severe Heart Failure: Chronic heart failure (NYHA Class IV). * End-Stage Liver Disease: Participants with end-stage liver disease. * Solid Organ Transplantation: History of solid organ transplantation or awaiting solid organ transplantation. * Malignant Tumors: Participants with a history of malignant tumors. * Other Serious Conditions: Any other serious medical conditions that may interfere with the study or pose a risk to the participant.

Primary outcome measure(s)

Cardiovascular death — From enrollment to the next 52 weeks
sudden cardiac death or death due to myocardial infarction, heart failure, stroke, or other cardiovascular causes.
Non-fatal myocardial infarction — From enrollment to the next 52 weeks
Including spontaneous, STEMI, NSTEMI, PCI-related, CABG-related, and silent acute myocardial infarction
Non-fatal stroke — From enrollment to the next 52 weeks
Meet any one of the following criteria: * Acute neurological dysfunction documented by CT/MRI, attributable to vascular causes with other etiologies excluded; ② Transient ischemic attack (TIA) lasting \<24 hours; ③ Microhemorrhage: Round hypointense lesions \<5-10 mm on MRI.

Trial sites (1)

Facility	City	Region	Status
Guangdong Provincial Hospital of Traditional Chinese Medicine	Guangzhou	Guangdong

More Guangdong Provincial Hospital of Traditional Chinese Medicine trials in China

Baduanjin-eight-silken-movement With Self-efficacy Building for Patients With Chronic Heart Failure (BESMILE-HF Study) Recruiting

Study on Heart Failure with Preserved Ejection Fraction with Qishen Granules Recruiting

Transcutaneous Auricular Vagus Nerve Stimulation Combined With Lifestyle Intervention for Visceral Fat Reduction in Adults With Overweight or Obesity Starting soon

Endoscopic Nipple-Sparing Mastectomy (E-NSM) With Immediate Multistage Autologous Fat Grafting(IMAFG) for Total Breast Reconstruction Via the Axillary Incision Enrolling by invitation

Other trials for the same condition

Application of QDSA Platform in Cerebrovascular Diseases Recruiting

App and Body Fat Scale in the Management of Overweight Patients Recruiting

A Clinical Study on Using Multimodal Ultrasound to Assess Muscle Mass in Metabolic Diseases Recruiting

Eradication of Helicobacter Pylori Improves Metabolic Syndrome Through Modulation of Gut Microbiota. Recruiting

Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06908473 on ClinicalTrials.gov ↗ ← All trials in China